Skip to main content
SpringerLink
Log in

Radiosensitizer für hypoxisches Tumorgewebe bei Zervixkarzinom

  • Literatur kompakt_Mammakarzinom und gynäkologische Tumoren
  • Published:
Im Focus Onkologie Aims and scope

Cisplatin-basierte Radiochemotherapien gelten als Standard in der Behandlung des fortgeschrittenen Zervixkarzinoms. Die Erweiterung um das selektiv unter hypoxischen Bedingungen aktive Tirapazamin könnte die relativ hohe Rezidivrate senken helfen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • DiSilvestro PA et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014;32(5):458-64.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Wolfgang Zimmermann

Authors
  1. Wolfgang Zimmermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zimmermann, W. Radiosensitizer für hypoxisches Tumorgewebe bei Zervixkarzinom. Im Focus Onkologie 17, 27 (2014). https://doi.org/10.1007/s15015-014-1213-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-014-1213-z

Search

Navigation